Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Insight, 2019 - ResearchAndMarkets.com

The "Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Insight, 2019 offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Basal Cell Carcinoma (Basal Cell Epithelioma) development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

• The report provides a snapshot of the pipeline development for the Basal Cell Carcinoma (Basal Cell Epithelioma)
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Basal Cell Carcinoma (Basal Cell Epithelioma)
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Basal Cell Carcinoma (Basal Cell Epithelioma)
• The report also covers the dormant and discontinued pipeline projects related to the Basal Cell Carcinoma (Basal Cell Epithelioma)

Topics Covered

1. Report Introduction

2. Basal Cell Carcinoma (Basal Cell Epithelioma) Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical and Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

Companies Featured

• Genentech Inc.
• Ascend Biopharmaceuticals Ltd.
• PellePharm Inc.
• HedgePath Pharmaceuticals Inc.
• biosceptreShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd.
• Biofrontera AG
• Provectus Biopharmaceuticals Inc.
• Novartis
• Hoffmann-La Roche
• Regeneron Pharmaceuticals
• Will-Pharma
• Blaze Bioscience Australia Pty. Ltd.
• Redx Pharma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/38pqsl/basal_cell?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190313005372/en/